Precipio Diagnostics LLC, based in New Haven, Conn., provides pathology diagnostic services to community oncologists and hospitals. Led by CEO Ilan Danieli, the company has 14 employees and has exclusively licensed several diagnostic technologies developed at Yale, which it is bringing to market. It commenced sales about a year and a half prior to the article and has produced more than 800 diagnostic reports for patients worldwide. The company raised $1.8M in Series B funding from several investors. Backers included Connecticut Innovations, which invested $750,000 through its Eli Whitney Fund and whose managing director Kevin Crowley joined Precipio’s board. Other participants were Ironwood Capital, Enhanced Capital, Kuzari Capital and individual investors; CI had previously provided a $500k loan in 2012 through the Bioscience Facilities Fund.

Total raised

$2M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2013